At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KZR Kezar Life Sciences Inc.
Market Closed 12-20 16:00:00 EST
6.38
-0.14
-2.15%
盘后6.36
-0.02-0.31%
19:14 EST
High6.75
Low6.35
Vol75.04K
Open6.49
D1 Closing6.52
Amplitude6.14%
Mkt Cap46.55M
Tradable Cap28.99M
Total Shares7.30M
T/O488.07K
T/O Rate1.65%
Tradable Shares4.54M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Kezar Life Sciences Is Maintained at Equal-Weight by Wells Fargo
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.